Clearmind Medicine Inc.

NasdaqCM CMND

Clearmind Medicine Inc. Gross Profit for the year ending October 31, 2023: USD -56.34 K

Clearmind Medicine Inc. Gross Profit is USD -56.34 K for the year ending October 31, 2023, a 32.28% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Clearmind Medicine Inc. Gross Profit for the year ending October 31, 2022 was USD -83.20 K, a -3,907.86% change year over year.
Clearmind Medicine Inc. Gross Profit for the year ending October 31, 2021 was USD -2.08 K, a 0.00% change year over year.
Clearmind Medicine Inc. Gross Profit for the year ending October 31, 2020 was USD 0.00, a 0.00% change year over year.
Clearmind Medicine Inc. Gross Profit for the year ending October 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqCM: CMND

Clearmind Medicine Inc.

CEO	Dr. Adi Zuloff-Shani Ph.D.
IPO Date	Nov. 15, 2022
Location	Canada
Headquarters	1220 West 6th Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals Mental Health

Description

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key trends

Past 5 years